Navigation Links
Amgen Announces 2014 Third Quarter Dividend
Date:7/25/2014

constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.  Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  Our efforts to integrate the operations of companies we have acquired may not be successful.  Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Cuyler Mayer, 805-447-6332 (media)
Arvind Sood, 805-447-1060 (investors)

Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO

 

 


'/>"/>
SOURCE Amgen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
2. Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
3. Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
4. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
6. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
7. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
8. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
9. Amgen And Servier Complete Product Collaboration Transaction
10. Amgen Announces 2013 Third Quarter Dividend
11. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... March 30, 2015 US-Australian drug discovery company, ... subsidiary, CanTx, Inc., and Yale University, on March 27 ... data was presented as an oral presentation by Professor ... School to the 62 nd Annual Scientific Meeting ... San Francisco, CA. In both ...
(Date:3/30/2015)... March 29, 2015 A two-day workshop ... States and plenary talks by four leading photonics researchers ... + Optoelectronics next month in Prague, Czech Republic. ... 17 conferences alongside a two-day exhibition. Sponsored by ... the event will run 13-16 April in the Clarion ...
(Date:3/29/2015)... , March 29, 2015  Caris Life ... in which Caris Molecular Intelligence®, the company,s panomic, ... and differences between several rare and difficult to ... that have the potential to improve patient outcomes. ... B at the Society of Gynecologic Oncology (SGO) ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... CAMBRIDGE, Mass., Feb. 17 Idenix Pharmaceuticals, Inc. (Nasdaq: ... and development of drugs for the treatment of human viral ... the fourth quarter and year ended December 31, 2008. At ... totaled $46.1 million. Business Highlights , ...
... Relationships Weaken in Many CountriesNEW YORK, Feb. 17 New ... the five major European countries -- the UK, Germany, Spain ... key sales and service activities. Merck takes the top ... UK and Germany. In 2008, Merck and Novartis tied ...
... Inc. (OTC:,SPOM - News), a leading developer of biosensor ... today that it,has appointed Med Tech and Med Care ... US market. , Med Tech ... the healthcare industry and operate with manufacturers,of medical products ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 2Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 3Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 4Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 5Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 6Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 7SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... 2013) For nearly half a century, contact lenses ... delivery that may someday replace eye drops, but achieving ... at Massachusetts Eye and Ear/Harvard Medical School Department of ... Technology are one step closer to an eye drop-free ...
... drives the development of tumours in over one per cent ... the gene CUX1 has been broadly linked to cancer development. ... biological pathway is activated that increases tumour growth. Drugs that ... clinic and are in development thus highlighting a potential new ...
... meets the eye following even a mild traumatic brain injury. ... reported in Nature suggest that the brain,s protective ... Using a newly developed mouse trauma model, senior author Dorian ... and Stroke (NINDS), part of the National Institutes of Health, ...
Cached Biology News:Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month 2Gene promotes 1 in 100 of tumors 2Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... This product is designed to deparaffinize and ... formalin fixed paraffin-embedded tissue sections mounted on ... melting the paraffin at the high temperature ... with emulsification of the paraffin by detergent. ...
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Biology Products: